Nadine Houédé Discusses Prostate Cancer Screening
Prostate cancer screening avoids automatic diagnostic pathways, as elevated prostate-specific antigen levels and detected cancer cells do not always mandate immediate treatment or biopsies, according to an interview with oncologist Nadine Houédé.
- Prostate cancer remains the most frequent cancer in men, with nearly 60,000 new cases diagnosed in France in 2018.
- An elevated PSA level does not automatically indicate cancer; 70 percent of high PSA readings stem from other conditions such as urinary infections, prostatitis, or benign prostatic hyperplasia, per Roche France data.
- Under current Association française d’urologie guidelines, low-risk indolent tumors often qualify for active surveillance rather than immediate therapeutic intervention.
Screening Realities and Genetic Risk Factors
Prostate cancer detection does not follow a universal mandate, primarily because of the existence of indolent forms. These slow-progressing tumors may never impact patient health, meaning routine screening carries a documented risk of overdiagnosis and unnecessary interventions that can alter urinary and sexual functions. Santé sur le Net reported that individual screening decisions are typically discussed with a physician for men between 50 and 70 years old, factoring in age and genetic predispositions. Mutations in the BRCA2 gene, which normally helps repair cellular DNA, increase the probability of developing aggressive forms of the disease.
PSA Levels and Physical Exams Provide Initial Warnings
The biomarker prostate-specific antigen serves as an initial warning flag rather than a definitive diagnosis. According to Roche France data, a low PSA level fails to rule out cancer in roughly 10 percent of cases. Conversely, an elevated reading requires a secondary blood assay to confirm persistence before clinicians order imaging or biopsies. Complementing blood tests, the digital rectal examination remains a component of clinical evaluations under the 2024–2026 guidelines issued by the Association française d’urologie. While the exam can encounter patient hesitation, it allows clinicians to evaluate prostate consistency, noting that a normal feel does not completely exclude malignancy.
Biopsy Thresholds and Active Surveillance Protocols
When physical exams or persistent PSA elevations reveal abnormalities, magnetic resonance imaging helps target suspicious zones prior to any tissue sampling. Biopsies are performed under local anesthesia in outpatient settings, but discovering malignant cells does not always trigger immediate surgery or radiation. For slow-growing tumors characterized by low PSA and minimal tumor volume, clinicians frequently utilize active surveillance. Data outlined on Santé sur le Net indicate that roughly half of patients enrolled in active surveillance programs avoid therapeutic treatment for at least three years following diagnosis, with intervention reserved exclusively for documented disease progression.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.